Kringle Pharma, Inc. (TSE: 4884)
Health Care · Biotechnology · JP
¥430.00
+6.17% today · -10.0% 1Y
Kringle Pharma, Inc. (TSE: 4884) operates in the Biotechnology industry within the Health Care sector. The company is valued at $22.67M and employs 17 people.
Over the last twelve months the share price has lost 10.0%, trading between 287.00 and 601.00.
Tweenvest scores Kringle Pharma, Inc. across four factors: quality 34/100, value 60/100, growth 0/100. Its strongest factor is value.
4884 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $22.67M
- Revenue (TTM)
- $2.11M
- P/E
- —
- EPS
- -110.24
- Dividend yield
- —
- Beta (5Y)
- 0.41
- 52-week high
- ¥601.00
- 52-week low
- ¥287.00
- Avg volume (3M)
- —
- Shares outstanding
- 8.38M
- Employees
- 17
- Next earnings
- —
About Kringle Pharma, Inc.
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
- ISIN
- JP3270790003
- Founded
- 2001
- Listed since
- Dec 28, 2020
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.